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The meningeal involvement is rare in acute promyelocytic leukemia. We experienced a 
39-year-old woman who achieved complete remission with all-trans retinoic acid, idar-
ubicin and cytarabine therapy. Several months later, she complained of non-specific 
headache. Her complete blood cell count was normal, but magnetic resonance image 
of brain revealed focal meningeal enhancement and cerebrospinal fluid showed leukemic 
promyelocytes and PML/RARA rearrangement. Bone marrow study showed hematologic, 
cytogenetic and molecular remission. She was treated with intrathecal and systemic che-
motherapy and whole brain radiotherapy. The patient has survived for 68 months since 
the last systemic chemotherapy.
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INTRODUCTION
  Acute promyelocytic leukemia (APL) is a specific type 
of acute myeloid leukemia (AML) characterized by the pres-
ence of abnormal promyelocytes in bone marrow and periph-
eral blood, young age at presentation, specific chromosomal 
abnormalities, coagulopathy, and a unique response to treat-
ment with retinoic acid. Until recently, combination of 
all-trans retinoic acid (ATRA) and chemotherapy with cytar-
abine and anthracyclines has been the standard treatment 
for APL. Although treatment with ATRA has improved the 
outcome of APL, early bleeding due to coagulopathy and 
relapse are the main causes of death in patients with APL 
[1].
   APL may relapse in central nervous system (CNS). 
However, CNS involvement at relapse is rare and is generally 
associated with a poor prognosis. We present a case of 
long-term survival in an APL patient who had achieved 
hematologic and molecular complete remission (CR) after 
treatment of meningeal relapse using ATRA, idarubicin and 
cytarabine.
CASE REPORT
  A 39-year-old woman presented with headache and 
petechiae. Her complete blood count (CBC) showed a white 
blood cell (WBC) count of 8,600/μL consisting of 75% blasts, 
hemoglobin level of 9.4 g/dL, and platelet count of 13,000/μL. 
Coagulation test showed prothrombin time of 13.5 sec, partial 
thromboplastin time of 26.1 sec, and fibrinogen level of 
80 mg/dL. APL was diagnosed on the basis of findings from 
bone marrow (BM) examination, and was confirmed by chro-
mosomal analysis, which indicated the presence of t(15;17) 
(q22;q11.2) and molecular analysis, which indicated the pres-
ence of promyelocytic leukemia (PML)/retinoic acid re-
ceptor-a (RARA) rearrangement. Induction chemotherapy 
with idarubicin (intravenous administration of idarubicin 
12 mg/m
2/day on days 2, 4, 6, and 8) and ATRA (45 mg/m
2) 
was administered to achieve CR. BM examination revealed 
normal karyotype and absence of the PML/RARA rearrange-
ment. The patient received consolidation therapy with 2 
consecutive courses of idarubicin and 1 course of mitoxan-
trone, followed by maintenance therapy with ATRA (45 
mg/m
2 on days 1-15, every other month for 2 years). 
  After 17 months, the patient complained of non-specific 
headache for 1 month. Her physical examination was un-Korean J Hematol 2010;45:208-10.
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Fig. 1. Enhanced T1-weighted magnetic resonance image showing focal
meningeal enhancement (arrow) in the right parietal lobe.
Fig. 2. Microscopic finding of cerebrospinal fluid showing numerous 
leukemic promyelocytes with prominent nuclear irregularities and 
variably granulated cytoplasms (Wright stain; ×1,000).
remarkable and her CBC was normal. Enhanced T1-weighted 
magnetic resonance image showed focal meningeal enhance-
ment in the right parietal lobe (Fig. 1). Cerebrospinal fluid 
(CSF) microscopic finding showed numerous leukemic pro-
myelocytes-containing prominent nuclear irregularities and 
variably granulated cytoplasm (Fig. 2) and PML/RARA re-
arrangement was detected. BM study showed hematologic, 
cytogenetic, and molecular CR. The patient was diagnosed 
with meningeal relapse of APL and treated with intrathecal 
administration of methotrexate and cytarabine (methotrexate 
12 mg and cytarabine 50 mg administered 3 times a week 
until the WBC count in the CSF reached zero), followed 
by whole-brain radiotherapy and systemic chemotherapy 
(cytarabine 2.0 g/m
2 I. V.  b. i. d . o n  d ays 1-3,  et o p o side  70 
mg/m
2 I.V. on days 1-4). The patient has survived for 68 
months since the last systemic chemotherapy.
DISCUSSION
  Extramedullary involvement at relapse is rarely observed 
in patients with APL. Skin, CNS, middle ear, lung, lymph 
node, mediastinum, thymus, spine, breast, pelvis, and gin-
gival are the common extramedullary sites. The skin is the 
most common extramedullary site [2].
  The symptoms of CNS involvement in APL are headache, 
vertigo, nausea, vomiting, visual disturbance, motor weak-
ness, and seizure. In our case, the patient complained of 
non-specific headache. Although meningeal infiltration of 
leukemia is rare, CSF should be examined when symptoms 
of suspected CNS involvement are present. Interestingly, 
in our patient, CNS relapse did not coincide with hematologic 
and molecular relapse. Among the reported cases of APL, 
6 continued to show hematologic and molecular remission 
despite CNS relapse [3-7]. 
  ATRA induces differentiation of abnormal promyelocytes 
into mature granulocytes and induces CR in 80-90% of newly 
diagnosed and first-relapsed cases of APL [1, 8, 9]. After 
the advent of ATRA treatment, an increasing number of 
APL cases with the involvement of extramedullary sites at 
relapse have been reported. Thus, ATRA treatment may 
predispose APL patients to extramedullary relapse. Several 
biologic effects such as ATRA-mediated increase in the ex-
pression of certain adhesion molecules (e.g., CD11c, CD13, 
and CD56) have been suggested to play a role in extra-
medullary involvement of leukemic cells [10, 11]. A 
GIMEMA study compared the relapse pattern in APL patients 
receiving different treatments (ATRA+chemotherapy group 
vs. chemotherapy alone). Unlike patients receiving chemo-
therapy alone, patients receiving ATRA and chemotherapy 
did not have an increased risk of involvement of extra-
medullary sites at relapse. However, patients receiving ATRA 
had a higher prevalence of CNS involvement. These findings 
suggest that with the advent of ATRA and subsequent combi-
nation chemotherapy, a substantially higher fraction of pa-
tients who achieve long-term remission are at the risk of 
developing CNS relapse than patients who were treated with 
chemotherapy alone in the past [12].
  The prognosis of CNS relapse in APL is generally poor. 
In particular, patients with multifocal CNS involvement had 
short survival time [3, 8]. Our findings indicate that after 
multimodal treatment, patients with focal involvement of 
the CNS have longer survival times than patients with multi-
focal involvement of the CNS. Treatment of CNS relapse 
consists of intrathecal chemotherapy, radiation therapy, sys-
temic chemotherapy with high-dose cytarabine, and treat-
ment with agents such as ATRA. Although ATRA does not 
cross the blood-brain-barrier (BBB), it induces the differ-
entiation of APL blasts present in the CSF of patients with 
CNS relapse [13]. High-dose cytarabine and arsenic trioxide 
(AS2O3) pass through the BBB and could be effective for 
APL patients with CNS relapse [14, 15].
  In summary, we presente a case of long-term survival 
in an APL patient with isolated meningeal relapse. CNS Korean J Hematol 2010;45:208-10.
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is the possible site of relapse in patients with CR after initial 
treatment. Therefore, precise evaluation and diagnosis by 
using approaches such as lumbar puncture and CSF examina-
tion should be performed, if CNS symptoms occur in patients 
with APL. 
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